- Home
- NXTC vs SNTI Comparison
NXTC vs SNTI Comparison
Compare NXTC & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- SNTI
- Stock Information
- Founded
- NXTC 2015
- SNTI 2016
- Country
- NXTC United States
- SNTI United States
- Employees
- NXTC N/A
- SNTI N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- SNTI Health Care
- Exchange
- NXTC Nasdaq
- SNTI Nasdaq
- Market Cap
- NXTC 23.0M
- SNTI 19.1M
- IPO Year
- NXTC 2019
- SNTI N/A
- Fundamental
- Price
- NXTC $0.79
- SNTI $4.67
- Analyst Decision
- NXTC Strong Buy
- SNTI Strong Buy
- Analyst Count
- NXTC 2
- SNTI 1
- Target Price
- NXTC $4.00
- SNTI $12.00
- AVG Volume (30 Days)
- NXTC 201.3K
- SNTI 115.8K
- Earning Date
- NXTC 11-07-2024
- SNTI 11-14-2024
- Dividend Yield
- NXTC N/A
- SNTI N/A
- EPS Growth
- NXTC N/A
- SNTI N/A
- EPS
- NXTC N/A
- SNTI N/A
- Revenue
- NXTC N/A
- SNTI N/A
- Revenue This Year
- NXTC N/A
- SNTI $11.52
- Revenue Next Year
- NXTC N/A
- SNTI $78.57
- P/E Ratio
- NXTC N/A
- SNTI N/A
- Revenue Growth
- NXTC N/A
- SNTI N/A
- 52 Week Low
- NXTC $0.76
- SNTI $1.52
- 52 Week High
- NXTC $2.57
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- NXTC 36.33
- SNTI 56.65
- Support Level
- NXTC $0.76
- SNTI $3.72
- Resistance Level
- NXTC $0.83
- SNTI $4.93
- Average True Range (ATR)
- NXTC 0.07
- SNTI 0.46
- MACD
- NXTC 0.01
- SNTI 0.01
- Stochastic Oscillator
- NXTC 14.87
- SNTI 81.82
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.